Vor Biopharma VOR 深 沪
等待开盘 11-14 09:30:00 美东时间
9.75
-0.310
-3.08%
华盛通- 最 高10.45
- 今 开9.96
- 成交量 86.92万股
- 最 低 9.50
- 昨 收 10.06
- 总市值 6670.07万
- 52周最高 65.80
- 市盈率 静 --
- 换手率 12.71%
- 52周最低 2.622
- 委 比 -27.78%
- 总股本 684.11万
- 历史最高 1272.40
- 量 比 0.38
- 振 幅 9.44%
- 历史最低 2.622
- 每 手 1
- 风险率 12.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多UPDATE: Vor Biopharma Q3 Adj. EPS $(3.33) Misses $(3.25) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(3.33) per share which missed the analyst consensus estimate of $(3.25) by 2.37 percent. This is a 58.39 percent increase over losses of $(8.00) per share from the
59分钟前
Vor Biopharma Launches $100M Common Stock Offering
Vor Biopharma Inc. (Nasdaq: VOR) (Vor Bio), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced that it has commenced an underwritten public offering of
11-11 05:03
Vor Bio Announced Telitacicept Achieved Primary Endpoint Of Reducing Proteinuria In Stage A Of Phase 3 Clinical Study For IgA Nephropathy In China; Statistically Significant Benefits Also Achieved Across All Key Secondary Endpoints
Treatment with telitacicept for 39 weeks resulted in a rapid, clinically meaningful, and statistically significant reduction in proteinuria, with a favorable safety profileTelitacicept demonstrated a 55% reduction in
11-09 00:55
Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio granted stock options and RSUs to 20 new employees on October 15, 2025, as inducements to employment. The stock options, totaling 113,478 shares with an exercise price of $30.22, and RSUs for 24,319 shares, vest over four years. Options vest 25% after one year, with remaining shares vesting monthly; RSUs vest quarterly. The grants align with Nasdaq rules and the 2023 Inducement Plan. Vor Bio focuses on developing treatment for autoimmune ...
10-31 20:30
美股大行评级 | 275美元！美银证券上调英伟达目标价；花旗上调思佳讯评级至"中性"，目标价从66美元升至91美元
今日重点评级关注：HC Wainwright & Co.：维持Unicycive Therapeutics"买入"评级，目标价从9美元升至22美元；花旗：维持Arcus Biosciences"买入"评级，目标价从54美元升至56美元
10-30 14:22
Vor Bio's Collaborator, RemeGen, Presents 48-Week Open-Label Extension Data From Phase 3 Study In China Evaluating Telitacicept In Patients With gMG At AANEM Annual Meeting
Telitacicept delivered consistent quality-of-life improvement across both treatment and placebo crossover arms100% of patients on telitacicept for 48 weeks achieved ≥2-point Myasthenia Gravis Activities of Daily Living
10-29 23:03
Telitacicept Demonstrates Sustained Efficacy and Favorable Safety Profile in 48-Week China Phase 3 Open-Label Extension Generalized Myasthenia Gravis Data
Vor Bio announced positive 48-week open-label extension (OLE) results from RemeGen's Phase 3 study in China evaluating telitacicept in generalized myasthenia gravis (gMG). Patients achieved significant improvements in MG-ADL and QMG scores, with all telitacicept-treated patients showing a mean reduction of -7.5 in MG-ADL and 96.2% reaching ≥3-point improvement. Telitacicept demonstrated consistent efficacy and a favorable safety profile, supporti...
10-29 15:01
Douglas Elliman Announces International Expansion Into France And Monaco
Meeting American Demand for French properties, the U.S.'s Premier Luxury Real Estate Brokerage Forms Alliance with Renowned European Real Estate Leaders Philippe Curutchet, Fredrik Lilloe, and Edward de Mallet
10-29 01:07
Major Moves: Fifth Third, HEICO, Transdigm, Cytokinetics, Vor Biopharma
Insiders have been trading these 5 stocks: (($FITB)), (($HEI)), (($TDG)), (($CY...
10-25 21:01
Vor Bio to Host Webcast on Late-Breaking China Phase 3 Telitacicept Data in Primary Sjögren’s Disease
Vor Bio Hosts Webcast on Telitacicept Phase 3 Data in Primary Sjögren’s Disease. Date: October 28, 2025 @ 4:30 PM ET. Discuss key results with Ronald van Vollenhoven. Register: [link]. Analyst Q&A: [link]. Replay available at [link].
10-22 20:30
